Article DOI: https://doi.org/10.3201/eid2609.191123

Leuconostoc lactis and *Staphylococcus nepalensis* Bacteremia, Japan

Appendix

Appendix Table 1. Antimicrobial susceptibility of *L. lactis* according to Clinical and Laboratory Standards Institute (CLSI) criteria*

Antimicrobial drug	MIC	Susceptibility
PCG	0.5	S
AMPC	1	S
AMPC/CVA	≥8	–
CTM	≥8	–
CDTR-PI	≥2	–
CTX	≥8	–
CTRX	≥8	–
CZOP	≥8	–
CFPM	≥4	–
MEPM	≥4	–
EM	≤0.12	–
AZM	≤0.12	–
CLDM	≤0.12	–
MINO	1	S
CP	≤4	S
VCM	≥2	–
LVFX	2	–
ST	≤0.5	–
RFP	≥8	–

*AMPC, ampicillin; AMPC/CVA, amoxicillin/clavulanate; AZM, azithromycin; CDTR-PI, cefditoren pivoxil; CFPM, cefepime; CLDM, clindamycin; CP, chloramphenicol; CTM, clarithromycin; CTRX, ceftriaxone; CTX, cefotaxime; CZOP, cefozopran; EM, erythromycin; LVFX, levofloxacin; MEPM, meropenem; MIC, minimal inhibitory concentration; MINO, minocycline; PCG, penicillin G; RFP, rifampin; S, susceptible; ST, sulfamethoxazole-trimethoprim; VCM, vancomycin.

Appendix Table 2. Antimicrobial susceptibility of *S. nepalensis* according to Clinical and Laboratory Standards Institute (CLSI) criteria

Antimicrobial drug	MIC	Susceptibility
PCG	≤0.06	R
MPIPC	0.5	S
ABPC	≤1	R
ABPC/SBT	≤2	S
CEZ	≤1	S
CMZ	≤4	S
CFX	≤4	–
IPM/CS	≤1	S
GM	≤1	S
ABK	≤1	–
EM	≥8	R
CLDM	2	I
MINO	≤1	S
VCM	1	S
TEIC	≤1	S
DAP	≤0.25	S
LVFX	≤0.5	S
FOM	≤4	S
ST	≤0.5	S
RFP	≤0.5	S
LZD	1	S
MUP	≤256	S

*ABK, arbekacin; ABPC/SBT, ampicillin/sulbactam; CEZ, cefazoline; CFX, cefotiam; CLDM, clindamycin; CMZ, cefmetazole; DAP, daptomycin; EM, erythromycin; FOM, fosfomycin; GM, gentamicin; I, intermediate; IPM/CS, imipenem/cilastatin; LVFX, levofloxacin; LZD, linezolid; MIC, minimal inhibitory concentration; MINO, minocycline; MPIPC, oxacillin; MUP, mupirocin; PCG, penicillin G; R, resistant; RFP, rifampin; S, susceptible; ST, sulfamethoxazole-trimethoprim; TEIC, teicoplanin; VCM, vancomycin.